canakinumab

Home
Ligands
canakinumab

GtoPdb Ligand ID: 6773

Synonyms: ACZ 885 | ACZ885 | Ilaris®

canakinumab is an approved drug (FDA (2009), EMA (2009))

Comment: Canakinumab targets interleukin-1β [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

References
1. Church LD, McDermott MF. (2009) Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther, 11 (1): 81-9. [PMID:19169963]
2. Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, Glynn RJ, Libby P, Ridker PM. (2018) Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. J Am Coll Cardiol, 71 (21): 2392-2401. [PMID:29544870]
3. Gram H, Di Padova FE. (2008) Antibodies to human IL-1β. Patent number: US7446175. Assignee: Novartis Ag. Priority date: 22/08/2000. Publication date: 04/11/2008.
4. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN et al.. (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med, 360 (23): 2416-25. [PMID:19494217]
5. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD et al.. (2017) Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med, 377 (12): 1119-1131. [PMID:28845751]
6. Ridker PM, Lüscher TF. (2014) Anti-inflammatory therapies for cardiovascular disease. Eur Heart J, 35 (27): 1782-91. [PMID:24864079]
7. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L et al.. (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med, 367 (25): 2396-406. [PMID:23252526]
8. Schieker M, Conaghan PG, Mindeholm L, Praestgaard J, Solomon DH, Scotti C, Gram H, Thuren T, Roubenoff R, Ridker PM. (2020) Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement : Exploratory Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial. Ann Intern Med, 173 (7): 509-515. [PMID:32744862]

References

1. Church LD, McDermott MF. (2009)
Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders.
Curr Opin Mol Ther, 11 (1): 81-9. [PMID:19169963]

2. Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, Glynn RJ, Libby P, Ridker PM. (2018)
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes.
J Am Coll Cardiol, 71 (21): 2392-2401. [PMID:29544870]

3. Gram H, Di Padova FE. (2008)
Antibodies to human IL-1β.
Patent number: US7446175. Assignee: Novartis Ag. Priority date: 22/08/2000. Publication date: 04/11/2008.

4. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN et al.. (2009)
Use of canakinumab in the cryopyrin-associated periodic syndrome.
N Engl J Med, 360 (23): 2416-25. [PMID:19494217]

5. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD et al.. (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
N Engl J Med, 377 (12): 1119-1131. [PMID:28845751]

6. Ridker PM, Lüscher TF. (2014)
Anti-inflammatory therapies for cardiovascular disease.
Eur Heart J, 35 (27): 1782-91. [PMID:24864079]

7. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L et al.. (2012)
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
N Engl J Med, 367 (25): 2396-406. [PMID:23252526]

8. Schieker M, Conaghan PG, Mindeholm L, Praestgaard J, Solomon DH, Scotti C, Gram H, Thuren T, Roubenoff R, Ridker PM. (2020)
Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement : Exploratory Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial.
Ann Intern Med, 173 (7): 509-515. [PMID:32744862]